Surgery Partners (SGRY) Scheduled to Post Quarterly Earnings on Tuesday

Surgery Partners (NASDAQ:SGRYGet Rating) is scheduled to release its earnings data before the market opens on Tuesday, May 3rd. Analysts expect Surgery Partners to post earnings of ($0.11) per share for the quarter. Surgery Partners has set its FY 2022 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Surgery Partners (NASDAQ:SGRYGet Rating) last released its quarterly earnings data on Monday, February 28th. The company reported $0.18 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.03). Surgery Partners had a negative return on equity of 0.53% and a negative net margin of 3.19%. The company had revenue of $610.20 million for the quarter, compared to analyst estimates of $625.91 million. During the same quarter in the prior year, the company earned $0.02 earnings per share. On average, analysts expect Surgery Partners to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of NASDAQ SGRY opened at $52.33 on Tuesday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.65 and a current ratio of 1.76. Surgery Partners has a 52-week low of $37.63 and a 52-week high of $69.58. The company has a 50 day simple moving average of $53.20. The firm has a market cap of $4.70 billion, a PE ratio of -42.20, a P/E/G ratio of 5.27 and a beta of 2.89.

In related news, Chairman Wayne S. Deveydt sold 966 shares of the stock in a transaction on Friday, March 11th. The shares were sold at an average price of $55.11, for a total transaction of $53,236.26. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider George Goodwin sold 25,525 shares of the stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $62.58, for a total transaction of $1,597,354.50. Following the transaction, the insider now directly owns 57,990 shares in the company, valued at $3,629,014.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 116,220 shares of company stock valued at $6,300,372. 4.30% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Norges Bank bought a new position in Surgery Partners during the fourth quarter worth $5,280,000. Barclays PLC lifted its stake in shares of Surgery Partners by 187.7% in the fourth quarter. Barclays PLC now owns 41,255 shares of the company’s stock valued at $2,204,000 after buying an additional 26,916 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Surgery Partners by 13.0% in the fourth quarter. BlackRock Inc. now owns 2,257,670 shares of the company’s stock valued at $120,580,000 after buying an additional 259,833 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Surgery Partners by 51.2% in the fourth quarter. Wells Fargo & Company MN now owns 46,445 shares of the company’s stock valued at $2,481,000 after buying an additional 15,734 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Surgery Partners by 2.9% in the fourth quarter. The Manufacturers Life Insurance Company now owns 17,565 shares of the company’s stock valued at $937,000 after buying an additional 502 shares in the last quarter.

SGRY has been the subject of several recent research reports. SVB Leerink upped their price target on shares of Surgery Partners from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, March 2nd. Royal Bank of Canada decreased their price target on shares of Surgery Partners from $70.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, March 1st. StockNews.com upgraded shares of Surgery Partners from a “sell” rating to a “hold” rating in a research report on Tuesday, March 29th. JPMorgan Chase & Co. upped their price target on shares of Surgery Partners from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Wednesday, March 2nd. Finally, Zacks Investment Research cut shares of Surgery Partners from a “buy” rating to a “hold” rating in a research report on Wednesday, March 2nd. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $57.86.

Surgery Partners Company Profile (Get Rating)

Surgery Partners, Inc, through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.

Read More

Earnings History for Surgery Partners (NASDAQ:SGRY)

Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.